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Abstract
Background: Multiple sclerosis (MS) is an incurable chronic disease that predominantly affects young adults. It has a
high socio-economic impact which increases as disability progresses. An assessment of the real costs of MS may
contribute to our knowledge of the disease and to treat it more efficiently. Our objective is to assess the direct and
indirect costs of MS from a societal perspective, in patients monitored in our MS Unit (Baix Llobregat, Catalonia) and
grouped according to their disability (EDSS).
Methods: We analysed data from 200 MS patients, who answered a questionnaire on resource consumption,
employment and economical status. Mean age was 41.6 years, mean EDSS 2.7, 65.5% of patients were female, 79.5% had
a relapsing-remitting course, and 67.5% of them were receiving immunomodulatory treatment (IT). Patients were
grouped into five EDSS stages. Data from the questionnaires, hospital charts, Catalan Health Service tariffs, and figures
from Catalan Institute of Statistics were used to calculate the direct and indirect costs. The cost-of-illness method, and
the human capital approach for indirect costs, were applied. Sensitivity analyses were performed to strengthen results.
Results: The mean total annual cost of MS per patient results 24272 euros. This cost varied according to EDSS: 14327
euros (EDSS = 0), 18837 euros (EDSS = 1–3), 27870 euros (EDSS = 3.5–5.5), 41198 euros (EDSS = 6–7) and 52841 euros
(EDSS>7.5). When the mean total annual costs was adjusted by the mean % of patients on IT in our Unit (31%) the result
was 19589 euros. The key-drivers for direct costs were IT in low EDSS stages, and caregiver costs in high stages. Indirect
costs were assessed in terms of the loss of productivity when patients stop working. Direct costs accounted for around
60% of total costs in all EDSS groups. IT accounts from 78% to 11% of direct costs, and decreased as disability progressed.
Conclusion: The total mean social costs of MS in a cohort from Baix Llobregat (Catalonia) were estimated at 24272
euros per patient/year, and ranged between 14327 euros (EDSS = 0) and 52841 euros (EDSS = 7.5–9.5). Total costs, and
particularly informal and direct costs, increased as the disability progressed. IT should be able to delay the progression
of disability to be efficient and not only effective.
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Multiple sclerosis (MS) is a chronic, demyelinating
inflammatory disease of the central nervous system
(CNS). Its aetiology is still unknown. In Spain, the preva-
lence of MS is 53–58 per 100000 [1,2]. It predominantly
affects young adults, with onset in third decade of life, and
females (ratio 2:1).
The prognosis for MS is unclear and is probably influ-
enced by genetic, biochemical and clinical factors. Life
expectancy seems to be relatively unaffected by MS, but
morbidity is considerable: 50% of patients will need help
to walk 10 years after diagnosis, according to natural his-
tory studies[3]. However, recent studies show that the dis-
ease has a more benign evolution[4].
MS represents the second most common cause of disabil-
ity in young adults, after road accidents, and has a high
socioeconomic impact.
In the last decade immunomodulatory treatments (IT)
have demonstrated their efficacy [5-8] in reducing the
number of relapses and, to a lesser extent, in slowing the
progression of the disability. However, these tendencies
have still not been confirmed for the long term. As treat-
ments are expensive, a question arises: are they efficient,
as well as being effective? In other words, because of their
beneficial effect and despite their elevated costs, is IT more
cost-saving than other therapeutic options in the long
term? Many cost-effectiveness analyses have been pub-
lished [9-17] with controversial results.
It is essential to assess the real cost of MS if we are to make
a cost-effectiveness analysis whose results can be applied
to daily clinical practice. Cost-utility analysis, a particular
type of cost-effectiveness analysis in which outcomes are
measured in terms of quality of life, may be particularly
appropriate for a disease like MS, as the assessment of
quality of life integrates physical and psychological com-
ponents of wellbeing which are affected by the disease
[18]. The cost of MS has been calculated in several coun-
tries [19-32]. These studies have shown the significant
economic impact of the disease and how it increases as
disability progresses. Cost-of-illness studies are of particu-
lar interest because they show costs of every item related
to the disease, thus revealing the main factors that contrib-
ute to the total costs.
Our study, the first of this type in our region (Catalonia,
Spain), attempts to assess the overall cost to society of MS,
calculated from a population of patients monitored in our
MS Unit. The approach that we used could be extended to
assess MS costs nationwide. Our intention was also to
show how the costs of MS change as the disease
progresses. Therefore, costs were calculated in different
stages of disability as measured by the EDSS (Expanded
Disability Status Scale).
A prevalence cost-of-illness analysis, like the one we
present, measures a disease's baseline costs to society.
Such an analysis could be useful for making decisions on
research investments. In contrast, incidence based cost
studies are more useful when estimating the effect of a
treatment on future costs.
Methods
We performed an observational cost-of-illness study
[33,34] for MS, a chronic disease, using a prevalence
approach, which entails estimating all costs for a particu-
lar population. We calculated the cost of MS per patient
over a given period of time (1 year) in a specific geograph-
ical area (Baix Llobregat, Catalonia, Spain). We estimated
costs for a group of patients whose results could be extrap-
olated to the general population (a "bottom-up"
approach). Data were collected in those patients retro-
spectively, as they referred to what occurred previous to
the moment when they answered the questionnaire elab-
orated. A "top down" approach would have involved
using data from database and statistical registers. Such an
approach is not suitable for a chronic disease like MS. It
would tend to underestimate total costs, as information
would not be available for calculating every cost in the
patient population (e.g. indirect costs).
Patients'
We calculated direct and indirect costs due to MS for a
group of 200 patients monitored in our MS Unit, who
answered, consecutively, a questionnaire elaborated for
that purpose. Recently diagnosed patients were excluded
from the study, as a complex, disability-focused question-
naire could have given them a negative perception of their
disease. Patients who were participating in clinical trials at
the time of the study were also excluded, as they tend to
consume more resources than the general MS population
(outpatients' visits, tests...). We considered the clinical
and demographic characteristics of the patients in the
study to be similar to those of the general MS population
seen in our clinics. No statistically significant differences
were found between patients who answered the question-
naire and patients who did not (except for the percentage
of patients on IT, see Table 1).
Patients' levels of disability were measured with the EDSS.
Patients were then put into five groups, representing clin-
ically relevant different disease stages: stage I (EDSS = 0,
the patient is not disabled but has been diagnosed of a
chronic disease): 23 patients; stage II (EDSS = 1–3, mini-
mally disabled): 107 patients; stage III (EDSS 3.5–5.5,
rather disabled): 42 patients; stage IV (EDSS = 6–7, patient
still capable of walking with aid): 17 patients; and stage VPage 2 of 8
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patients. Patients' EDSS scores were obtained from their
medical charts.
Data collection
The questionnaire was anonymous and voluntary. It was
mailed to 454 patients with a statement of informed con-
sent to be signed by patients and caregivers. A letter
explaining the purpose of the study was also sent to every
patient. We obtained 200 responses (44%). Data were col-
lected on socio-demographic and clinical characteristics;
work-status; resource consumption; and costs attributable
to MS during the previous 15–365 days. The length of the
recall period varied according to the item in question, to
minimize any possible bias due to a patient's lack of
memory. The recall periods for the different items were as
follows:
-previous year for hospitalisation, need for caregivers and
sick leave, due to MS
-previous 3 months for outpatient visits
-previous 15 days for drug treatments, rehabilitation, vis-
its to the General Practitioner, ambulance displacements,
laboratory-imaging tests, and days of leisure time and/or
daily activities lost due to MS.
A recall period of 1–3 months has been shown to be gen-
erally reliable for retrospective data. For more important
or less frequent events, such as hospitalisation, a 12-
month recall period is considered appropriate [25-
27,30,32].
Questions about home modifications referred to the full
duration of the disease. The unit costs for adaptations
were not available for our region. Therefore, we used the
mean cost per patient per year of home adaptations made
because of MS, which has previously been calculated in
the European Community [25-27,29].
Data obtained from questionnaires were verified and
completed with data taken from inpatient records, medi-
cal files and the Medical Records Department, to improve
reliability of the patients' responses. Data were then annu-
alised when necessary. The study period was one year,
from 1-8-2001 to 31-7-2002.
The Ethical Committee of the University Hospital of Bel-
lvitge and the Institute for Biomedical Investigation of
Bellvitge (Barcelona, Spain), where the study was carried
out, gave their approval for the whole project.
Unit costs
Unit costs were obtained from: Catalan Health Institute
tariffs (costs of: procedures, visits to physicians, hospitali-
sations); the Catalan Institute of Statistics (the minimum
hourly wage, the average costs of labour in each sector of
activity, the median time to find a job in Spain); market
prices for pharmacological treatments (Drugs and Chemists
Pharmacy Database of the General Council of Official Colleges
of Pharmacists, 2004); and investments required to over-
come architectural barriers. Every unit cost was updated to
the equivalent number of euros in 2004, as the resources
consumed in 2001 and 2004 did not differ greatly.
Direct costs
We calculated the direct costs by multiplying the resources
consumed per patient by their unit costs. The costs of hos-
pitalisation, ambulatory assistance, treatments, rehabilita-
tion, transport, investments to overcome architectural
barriers, disability aids, and informal care (provided by a
non-paid caregiver who was a relative in most cases) are
included as direct costs [25-27,30].
Indirect costs
We used a Human Capital Approach to estimate the indi-
rect costs. This approach involves analysing MS-attributa-
ble loss of productivity, in terms of morbidity and
mortality. The number of days lost due to sick leave and
changes in the work status of patients and caregivers
Table 1: The baseline characteristics of patients analysed.
N = 200 N = 254 p
Mean age -years- 41.6 42.1 0.6
Sex (%female) 65.5 63.3 0.6
EDSS (mean) 2.7 2.8 0.9
EDSS (median) 2 2 0.6
Mean disease duration (years) 12.3 11.9 0.7
Clinical form of MS (% of RR/SP/PP) 79.5/13/7.5 81.9/8.7/9.4 0.3
Mean number of relapses during the previous year 0.3 0.3 0.2
% of patients on IT 67.5 45.7 0.0
No differences were found between patients who answered the questionnaire (N = 200) and patients who did not answer it (N = 254), except for 
the percentage of patients on IT.
MS: multiple sclerosis. RR: relapsing-remitting. SP: secondary progressive. PP: primary progressive. IT: immunomodulatory treatmentPage 3 of 8
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in terms of life expectancy, is not significantly affected by
MS. Therefore it was considered irrelevant (equivalent to
0) in this study. A minimum hourly wage was applied to
patients who did not carry out "productive activities" in
the labour market (e.g, housewives), to avoid underesti-
mating indirect costs in this group of patients. For the rest
of the patients, we applied the salary cost per hour in each
professional sector, as described in the "National list of Eco-
nomic Activities in fourth trimester 2003 – CNAE 2003".
Thus, the results obtained should be considered a mini-
mum estimation of indirect costs.
Informal care costs
Informal care is provided by non-paid caregivers, who are
generally patients' family members. The costs of this
informal care were included in the direct costs [25-27,30].
We used a replacement cost of 50% of the minimum
hourly wage [19,30,32] This figure was selected as empir-
ical studies have estimated the value of unpaid labour as
being between 0.4 and 0.6 of potential earned income
[19]. The replacement cost was then multiplied by the
number of hours employed by the caregiver in taking care
of the patient. A specific questionnaire was answered by
the patient's caregiver, who reported the number of hours
employed in this activity. As the replacement cost is not
clearly standardized, a sensitivity analysis was performed.
Results are shown in Table 2. This analysis involved valu-
ing caregiver time at 30% and 100% of the minimum
hourly wage (extreme values previously employed in liter-
ature, [7,24,25]).
Ethical approval
The project obtained the approval of the Ethics Commit-
tees for the Hospital Universitario de Bellvitge and the
Instituto de Investigación Biomédica de Bellvitge
(IDIBELL), Barcelona, Spain.
All statistical analysis were performed using SPSS soft-
ware. X-2, Student's t and U- Mann-Whitney tests were
used.
Results
We analysed data from 200 patients with definite MS. The
average age was 41.6 (SD: 10.7), 65.5% of patients were
female, and 78.5% had relapsing-remitting MS. The mean
EDSS was 2.7 (SD: 2.2) and the median EDSS was 2. The
mean number of years from MS onset was 12.3 (SD: 8.39)
(Table 1).
All costs were calculated per patient per year in each EDSS
group. The mean cost per patient was calculated from the
total cost divided by the number of patients included in
the study.
Direct costs (Table 2) ranged from 8706 and 37062 euros
per patient per year, depending on the EDSS. Direct costs
were mostly due to pharmacological treatment (67.5% of
patients were on IT in the sample studied) and to informal
care. IT represented up to 78% of all direct costs in the
lowest EDSS stages. However, it only represented 11% of
all direct costs when patients reached EDSS >7. At this
stage, rehabilitation, investments to overcome architec-
tural barriers, disability aids and particularly informal care
contributed most to total direct costs (informal care costs
represent 60.4% of direct costs when EDSS >7). After a
sensitivity analysis, the overall trend remained as in the
primary analysis (Table 2): direct costs increased as disa-
bility progressed, and were higher than indirect costs.
Indirect costs (Table 3) reflect the productivity lost by
patients, caused by "short term sickness absence" (days of
sick leave) and "long term sickness-absence" (invalidity,
unemployment and other changes in work status caused
by MS). Indirect costs ranged from 5621 to 17161 euros
per patient per year. They increased as the EDSS stage
increased, and represented 34.6% of total costs. The key-
drivers of these costs were MS-attributable changes in
patients' work-status.
The total costs of MS per patient per year, including the
direct and indirect costs, are summarised in Table 4. The
mean annual total direct and indirect costs for an MS
patient in the sample studied (67.5% of patients on IT)
was 24272 euros. When we adjusted this figure to the per-
centage of patients receiving IT in our MS Unit (31%), the
total was 19589 euros. IT accounted for 34.5% of total
costs in the sample studied, and for 19% in our MS Unit
(mean per patient per year).
Discussion
The aim of this study was to perform a complete analysis
of the costs of MS, and to describe how costs change in dif-
ferent disability stages.
We have chosen a prevalence approach that is "bottom-
up", as described in the method section. We performed
the study from a social perspective, as this meant that all
costs generated by MS could be included (health-care and
non-health-care costs) independently of who pays for
them. This is the most extensive approach, and enables
data to be disaggregated for further analyses. This
approach also enabled us to classify costs according to dis-
ability. In addition, we could obtain the costs derived
from each disease-related item separately, which may be
useful when establishing adequate therapeutic strategies
and making cost-effectiveness analyses. An important dis-
advantage of this approach is the difficulty involved in
selecting a representative sample. However, the alterna-
tive "top-down" approaches (when data about diagnosesPage 4 of 8
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published sources), also have a significant disadvantage:
available data are more limited and mostly retrospective.
The sample we analysed in this study is representative of
the MS population attended in our MS Unit. It included
patients from the entire spectrum of the disease (66 %
with very mild MS, EDSS<3.5; 4% wheelchair bound;
1.5% bed-ridden; 7.5% with the primary progressive
form).
Table 3: The indirect costs of MS (the mean annual cost per patient per year, in euros).
EDSS 0 1.5–3.0 3.5–5.5 6.0–7.0 >7.5
Productivity losses in patients, due to:
1) Short term sickness absences, because of MS/others 902/0 1415/1155 1683/358 2113/0 0/0 1394/693
Sick leaves (number of days/year) because of MS 6.04 13.48 16.3 21.47 0 13.15
Sick leaves (number of days/year) because of other reasons 0.48 12.9 4.33 0 0 7.9
Work absences (number of hours/year) because of MS 35.04 14.65 30.2 0 0 18.2
2) Long term sickness absences (change in work-status) 4719 4046 7555 15048 15779 6326
% p. with premature work invalidity due to MS 0 15 38 70 82 26.5
% p. with premature retirement due to MS 0 0.9 0 0 9 1
% p. with reduction of worktime hours due to MS 4 1.8 2.4 0 0 2
% p. who changes-adaptates their work-status to their MS 13 4.7 4.7 0 0 5
% p. who do not change their work-status, despite their- MS 4 9 4.7 6 0 7
TOTAL indirect costs due strictily to MS 5621 5461 9238 17161 15779 7719
TOTAL INDIRECT costs (due to MS and related reasons) 5621 6616 9596 17161 15779 8412
% of total costs of MS attributable to indirect costs 39 35 34 42 30 35
Each column represents the costs calculated for each disability group of patients (p.), established according to their EDSS stages. The last column 
shows the costs calculated for the whole sample (N = 200). The number of work absences and the percentage of patients who changed their work-
status are also detailed, according to EDSS stages.
Table 2: The direct costs of MS (mean annual cost per patient per year, in euros).
EDSS 0 1–3 3.5–5.5 6–7 >7.5
• Medical visits in hospital, due to MS 124 198 262.9 238.7 157.6 204.4
• Medical visits in hospital, due to related diseases 10.4 33.7 01.1 78 03 43.2
• Complementary tests in hospital, due to MS 10.3 160.6 29.1 436.4 8.5 130.8
• Complementary tests in hospital, due to related diseases 14.5 10.0 10 05.2 33.0 24.5
• Visits to General Practitioner, due to MS 0 93.5 173.2 26.7 206.7 100.1
• Hospitalization, due to MS 0 29.4 42.7 123 135.8 42.6
• Ambulance displacements, due to MS 0 21.9 0 330.5 170.3 49.2
• Taxi displacements, due to MS 0 52.5 196.8 27.5 70.9 75.7
• Home adaptations, due to MS 0 237.4 838.3 2071.3 7188 874.3
• Car adaptations, due to MS 0 56 285.7 705.9 1272.3 220
• Workplace adaptations, due to MS 0 50.2 35.2 240.6 269.1 69.5
• Rehabilitation, due to MS 0 368.2 1077.2 1201.8 796 569.2
• Pharmacological treatment, due to MS 20.6 39.8 81 44.6 66.2 48.1
• Pharmacological treatment, due to related diseases 32.8 107.3 244.7 277.5 300.4 201.3
• Informal care, due to MS 1069 1856 5456 11555 22164 4831
informal care, when replacement costs vary 030–2122 1114–3713 3273–10011 0033–23111 13208–44328 2898–9661
• IMMUNOMODULATORY treatment, due to MS 6785 8815 9921 6584 4150 8377
Total direct costs, due to MS 8009 11979 18399 23587 36656 15591
Total directcosts, due to related diseases 07 242 325 451 400 269
TOTAL DIRECT COSTS 8706 12221 18724 24037 37062 15860
Total directcosts IT Informal care value = 30% MHW 8273 11479 16541 19415 28196 13927
Total directcosts IT Informal care value = 100% MHW 9759 14078 24179 35593 59226 20690
% of overall costs of MS attributable to direct costs 61 65 66 58 70 65
Each column reflects the data obtained from 5 different groups of patients, classified according to thier EDSS stage. The last column shows data 
calculated from the whole sample. A sensitivity analysis was performed, by varying the replacement costs used to value informal care (taken as 
either 30% or 100% of the minimun hourly wage [MHW])Page 5 of 8
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MS at different levels of disability. Therefore, we decided
to group patients into clinically relevant stages of disabil-
ity, in order to see whether the costs varied significantly
among such stages (even though some groups contained
a small number of patients). There were marked differ-
ences in costs among the five disability stages, particularly
for direct costs (Table 2). The differences among the stages
were less marked for indirect costs (Table 3). Total costs
increased as the EDSS stage increased (Tables 2, 3, 4).
Indirect costs were a little higher in stage IV than V (more
disabled patients). This is probably due to the small
number of patients in these groups. However, it also
reflects the fact that indirect costs may not differ much
between patients with EDSS ≥6 or ≥7.5. In both of these
stages, most patients are unable to work and their produc-
tivity losses are therefore similar. It is interesting to note
that even when patients have no disability (EDSS = 0), the
direct and indirect costs caused by MS are 14327 euros per
patient/year. Another surprising finding is that disabled
patients, with EDSS 3.5–5.5, did not use ambulances. This
is probably because such patients used taxis for transport,
as described in Table 2. The small sample size may have
contributed to this result.
The methodology used in our study has also been widely
employed in the literature. Therefore, comparisons of our
results with those obtained from similar studies carried
out in other countries may be possible. However, direct
comparisons with available data from other costs studies
can not be made because of differences in healthcare sys-
tems, healthcare usage, absolute and relative costs.
Major limitations of the study include: the retrospective
collection of data, and the small number of patients
involved (200). There was a low response rate to the ques-
tionnaire, which may have been due to the question-
naire's complexity. We did not carry out a second mailing,
and did not personally insist on patients responding in
order to guarantee their willingness. The fact that we did
not find statistically significant differences between
patients who responded to the questionnaire and those
who did not minimizes the possibility of a selection bias.
There was a higher proportion of patients on IT (67.5%)
in our sample than in the general MS population. This was
probably because treated patients tend to visit our MS
Unit frequently (for medical visits, collection of medica-
tion, procedures etc.). In addition, they may feel more
involved with the MS Unit and therefore may be more
willing to answer the questionnaire (47.5% of patients
who did not answer the questionnaire were on IT). We
made a rough estimation of costs for the general MS pop-
ulation by adjusting the costs [32] of IT to the percentage
of IT-treated patients in our MS Unit (specialised Unit at a
University Hospital). The results are detailed in Table 4.
They show that costs increased as EDSS stage increased, as
in the primary analysis.
Another limitation of the study was the lack of informa-
tion on costs attributable to MS-associated neuropsychiat-
ric complications and cognitive impairment. Such costs
were not specifically measured in our patients, even
though cognitive and neuropsychiatric factors have been
shown to have a significant impact on MS patients [18].
Table 4: The total costs of MS, in euros per patient per year, for the sample studied (N = 200) according to disability.
EDSS 0 1.0–3.0 3.5–5.5 6.0–7.0 7.5–9.5 mean
total costs (direct + indirect) 14327 18837 27869 41198 52841 24272
% patients on IM treatment our MS Unit 6 57 41 47 4 31
total costs adjusted by % of patients on IT in our MS Unit 7400 17589 23157 40273 48729 19589
% of global costs attributable to IT, in MS Unit 9 43 21 14 1 19
Disability -according to EDSS- mild moderate severe
Global costs of MS in Poland (Orlewska et al., 2005) 6572 9362 11078
"Italy (Amato et al, 2002) 7463 23088 35975
"Sweden (Heriksson et al., 2001) 18787 36470 91986
"Germany (Kobelt et al., 2000) 20000 39000 61000
"United Kingdom (Kobelt et al., 2000) 20000 38000 41500
"France (Murphy et al., 1998) 8000 16000 22400
"Germany (Murphy et al., 1998) 9088 8224 22804
"United Kingdom (Murphy et al., 1998) 20500 27004 58488
Costs were calculated for patients classified in the 5 EDSS groups (columns 1 to 5) and for the whole sample, N = 200, (column 6). The total costs 
were adjusted by the percentage of patients on IT (immunomodulatory treatment) in our MS Unit in 2004. Costs that have been reported in other 
countries have been converted into euros and are described below (also according to patients' disability).Page 6 of 8
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employed. Firstly, the "Human Capital Approach" has a
significant limitation. It tends to underestimate the costs
for people who are not in paid employment at the time of
the study. Therefore, results obtained using this approach
have to be considered a minimum estimation of costs. In
spite of this, it is the most commonly used method in the
literature. Secondly, if tariffs are used as unit costs when
no other opportunity costs are available -as in our case-
costs can be overestimated (by approximately 20%, as
reported in United Kingdom)[27] or underestimated (as
in Germany, where tariffs appear to include incentives for
a reduction in usage and are therefore lower than oppor-
tunity costs)[26]. This issue has not been resolved in
Spain, and may therefore lead to either an overestimation
or underestimation of total costs for society. Finally, infor-
mal care costs can be evaluated in different ways. In our
case, only a minority of caregivers (0–36%, depending on
EDSS stage) had to give up their remunerated work
because of the patient's MS, thus leading to productivity
losses (indirect costs). Therefore, in order to be consistent
and to obtain a better reflection of the informal care costs
in our sample, we considered informal care as a direct
cost. We used the replacement method to measure this
cost. A sensitivity analysis was performed by varying the
replacement costs used, which strengthened the results
obtained in the primary analysis.
We consider that this study represents an exhaustive esti-
mation of the real costs of MS. It shows that the direct
costs are higher than indirect costs, and that the overall
costs increase as the disability progresses. The main factors
that contribute to direct costs differ depending on the
EDSS stage. IT is the most important factor when the EDSS
is below 7. Informal care is the most significant factor
when the EDSS is above 7.5. IT accounts for 19% – 34%
of total costs, depending on the percentage of patients
treated (31% in our MS Unit, and 67.5% in the study sam-
ple).
Our results are consistent with other costs studies
reviewed in the literature [19-32], which also showed that
the costs of MS increased as disability progressed (Table
4). In our region, which has a public health care system, a
significant part of the cost is covered by the patient's fam-
ily, who act as unpaid caregivers. As in Italy[24], this is the
culturally accepted mode of care for MS patients in Cata-
lonia. Therefore, informal care expenses have been under-
estimated to date.
Despite the limitations described, cost-of-illness analyses
like this study, which are based on real MS population
data rather than on selected patients from trials, are
important. They can be used to perform cost-effectiveness
analyses which can demonstrate whether or not immu-
nomodulatory agents are cost-saving in the long term,
under real conditions of clinical practice.
Conclusion
The present study reflects the significant social and health-
care impact of a chronic disease like MS. This impact
increases with the progression of disability (EDSS).
The total mean societal costs of MS estimated in our sam-
ple, a cohort of MS patients monitored in our MS Unit in
Baix Llobregat (Catalonia, Spain), were 24272 euros per
patient/year. Costs ranged from 14327 euros (EDSS = 0)
to 52841 euros (EDSS = 7.5–9.5). The direct costs were
higher than indirect costs in all EDSS stages. This was
mostly due to IT use in lower EDSS stages, and to informal
care in higher EDSS stages.
Conclusions from this kind of analyses will be helpful for
clinicians and for health care authorities, as cost-of-illness
studies should be a first and indispensable step toward
analysing the cost-effectiveness of IT. The cost-effective-
ness of treatments is an increasingly important issue in
policy decision-making which helps to optimise available
resources.
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